Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

BET-BD1 Selective Neuroimaging probes for Alzheimer's disease research

Award Number: R01AG081195
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

BET-BD1 Selective Neuroimaging probes for Alzheimer's disease research - Project Summary Epigenetics refers to functional modifications to the genome that do not involve a change in the DNA sequence. Growing evidence have shown that modulation of epigenetic processes may be a new therapeutic approach applicable across most human diseases. The epigenetic “readers” have been implicated in multiple functions and associated with various human diseases, such as Alzheimer’s disease (AD). The bromodomain and extra- terminal domain (BET) family of proteins contain tandem bromodomains which bind to acetylated histones. Four BET members (BRD2, BRD3, BRD4 and BRDT) are found in humans, contain two bromodomains each (N- terminal bromodomain (BD1) or C-terminal bromodomain (BD2)). Recently, BET inhibitors have been reported to have a key impact on brain function, including learning and memory. Our overall goal is to develop PET radiotracers target BET-BD1 in the brain for comparison to disease states and for assessing in vivo BET-BD1 target engagement with BET drug treatment. Moreover, these techniques will accelerate the discovery of small molecule therapeutics that selectively interacts with the specific BET-BD1 domain. Currently, there are no PET tracers available for imaging BET-BD1 in the brain, although several BET inhibitors or selective BET-BD1 inhibitors have been reported or radiolabeled. The project is designed to perform IND-enabling studies for a novel PET imaging probe for BD1 domain of BET.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $804,605 )
2026	2026	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Aging Research	000	2	4/7/2026	EXTENSION WITH OR WITHOUT FUNDS	$804,605
														Subtotal = $804,605

Grand Total All Awards = $804,605

Top

All Categories

About

Search

Reports

Data Submission

Award Information

BET-BD1 Selective Neuroimaging probes for Alzheimer's disease research

Award Number: R01AG081195

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer